Healthcare Press

FDA Staff Proposes Narrow Approval for Lilly’s Alzheimer’s Drug

  • 📰 BNNBloomberg
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 50%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

US drug regulatory staffers are considering a more targeted approval for Eli Lilly & Co.’s experimental Alzheimer’s disease treatment than the company wants, potentially limiting the market for a would-be blockbuster.

Hungary and Vinci Buy Budapest Airport in $4.

What you should knowFirst 2024 Canada carbon rebates will be deposited today for some CanadiansThe big benefits of adopting a debt-free lifestyleMost young adults think retiring by 65 is outdated: surveyMany Canadians still feeling squeezed even as debt worries ease: insolvency firmBillionaire Family Builds a Real Estate Empire Fueled by TequilaCommercial real estate trends shifting toward purpose-built rentals: Re/Max reportChina Property Stocks Fall 20% From May High as Concerns LingerTaiwan...

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 83. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

US FDA staff flags concerns on MDMA-assisted PTSD treatmentExplore stories from Atlantic Canada.
Source: SaltWire Network - 🏆 45. / 63 Read more »